Muscle Study Group
The Muscle Study Group (MSG), is a consortium of scientific investigators from academic and research centers who are committed to the cooperative planning, implementation, analysis and reporting of controlled clinical trials and of other research for muscle and other neuromuscular diseases. The MSG aims to advance knowledge about the cause(s), pathogenesis, epidemiology, and clinical manifestations of muscle disease and related neuromuscular disorders and to develop and implement strategies to examine promising therapeutic interventions.
The MSG is committed to the principles of open and full scientific communication, peer review, full disclosure of potential conflicts of interest, and democratic governance of its organization and activities. The MSG is also interested in providing scientific and medical information to professionals and the public regarding experimental therapeutics.
The MSG began meeting in 1997 and is organized as an independent, nonprofit consortium of scientific investigators who conduct research at the institutions with which the investigators are affiliated.
The MSG strives to perform clinical trials in all of the neuromuscular diseases. Diseases studied by the MSG have included:
- Charcot-Marie-Tooth Disease 1A (CMT1A)
- Hyperkalemic and Hypokalemic Periodic Paralysis
- Inclusion Body Myositis
- Myasthenia Gravis
- Spinal Muscular Atrophy (SMA)
Muscle Study Group Executive Committee
Chair: Robert C. Griggs, MD (2014)
Co-Chair: Richard Barohn, MD (2014)
Investigator Members: Michael Shy, MD (2014); James Howard, MD (2015); Michael Hanna (2016)
Evaluator Member: Jackie Montes (2014)
Study Coordinator: Nina Gorham (2014)
Biostatistician: Michael P. McDermott, PhD (2014)
Director, MSG Coordination Center: Rabi Tawil, MD (2014)
Front Row: Nina Gorham, Richard Barohn, Robert Griggs and Michael Shy
Back Row: Jackie Montes, Carlayne Jackson, Michael McDermott and Charles Thornton
Absent: Ted Burns, John Kissel and Don Sanders